Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;50(5):388-93.
doi: 10.1097/MLR.0b013e3182422a3b.

Prioritization in comparative effectiveness research: the CANCERGEN Experience

Affiliations

Prioritization in comparative effectiveness research: the CANCERGEN Experience

Rahber Thariani et al. Med Care. 2012 May.

Abstract

Background: Systematic approaches to stakeholder-informed research prioritization are a central focus of comparative effectiveness research. Genomic testing in cancer is an ideal area to refine such approaches given rapid innovation and potentially significant impacts on patient outcomes.

Objective: To develop and pilot test a stakeholder-informed approach to prioritizing genomic tests for future study in collaboration with the cancer clinical trials consortium SWOG.

Methods: We conducted a landscape analysis to identify genomic tests in oncology using a systematic search of published and unpublished studies, and expert consultation. Clinically valid tests suitable for evaluation in a comparative study were presented to an external stakeholder group. Domains to guide the prioritization process were identified with stakeholder input, and stakeholders ranked tests using multiple voting rounds.

Results: A stakeholder group was created including representatives from patient-advocacy groups, payers, test developers, regulators, policy makers, and community-based oncologists. We identified 9 domains for research prioritization with stakeholder feedback: population impact; current standard of care, strength of association; potential clinical benefits, potential clinical harms, economic impacts, evidence of need, trial feasibility, and market factors. The landscape analysis identified 635 studies; of 9 tests deemed to have sufficient clinical validity, 6 were presented to stakeholders. Two tests in lung cancer (ERCC1 and EGFR) and 1 test in breast cancer (CEA/CA15-3/CA27.29) were identified as top research priorities.

Conclusions: Use of a diverse stakeholder group to inform research prioritization is feasible in a pragmatic and timely manner. Additional research is needed to optimize search strategies, stakeholder group composition, and integration with existing prioritization mechanisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Landscape Analysis and Test Selection Overview: CANCERGEN project milestones including landscape analysis, and stakeholder assessment.
Figure 2
Figure 2
Overall results, showing tests contributed by the landscape analysis through to stakeholder voting.
Figure 3
Figure 3
Sections of the TTP used to communicate with stakeholders

References

    1. Edwards RT, et al. Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units. Trials. 2008;9:64. - PMC - PubMed
    1. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther. 2010;87(3):351–5. - PubMed
    1. Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004;12(2-3):136–40. - PubMed
    1. Myers EW, Sanders GD, Ravi G, et al. Evaluating the Potential Use of Modeling and Value-of-Information Analysis for Future Research Prioritization Within the Evidence-based Practice Center Program. In: AHRQ, editor. Methods Future Research Needs Report. AHRQ; 2011. - PubMed
    1. Brown IT, et al. Medical technology horizon scanning. Australas Phys Eng Sci Med. 2005;28(3):200–3. - PubMed

Publication types

MeSH terms